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ABSTRACT
IgG4-related disease (IgG4-RD) is a recently recognized disorder, characterized 
by elevated serum IgG4 concentrations, dense tissue infiltration of IgG4-positive 
plasma cells and storiform fibrosis. Treatment is usually based on steroids, however, 
relapses and long-term adverse effects are frequent. We prospectively studied 5 
consecutive patients with histologically-proven IgG4-RD and renal involvement, 
treated with an extended Rituximab protocol combined with steroids. Two doses of 
intravenous cyclophosphamide were added in 4 patients.
Five patients with IgG-RD were investigated: three had tubulointerstitial nephritis 
(TIN), while two had retroperitoneal fibrosis (RPF). In the patients with TIN, renal 
biospy was repeated after 1 year.
In the patients with TIN, estimated glomerular filtration rate (eGFR) at 12 months 
increased from 9 to 24 ml/min per 1.73 m2; IgG/IgG4 decreased from 3,236/665 to 
706/51 mg/dl; C3/C4 increased from 49/6 to 99/27 mg/dl; CD20+ B-cells decreased 
from 8.7% to 0.5%;  Regulatory T-cells decreased from 7.2% to 2.5%. These 
functional and immunologic changes persisted at 24 months and in two patients at 
36 months. A repeat renal biopsy in the patients with TIN showed a dramatic decrease 
in interstitial plasma cell infiltrate with normalization of IgG4/IgG positive plasma 
cells. The patients with RPF showed a huge regression of retroperitoneal tissue. 
In this sample of patients with aggressive IgG4-RD and  renal involvement, 
treatment aimed at depleting B cells and decreasing antibody and cytokine production 
was associated with a substantial, persistent increase in eGFR, and a definite 
improvement in immunologic, radiologic and histological parameters.
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INTRODUCTION
IgG4-related disease (IgG4-RD) is a recently 
recognized, frequently multi-organ disorder 
characterized by tumefactive lesions or organ 
enlargement, elevated serum IgG4 concentrations, 
and peculiar histological features including  dense 
lymphoplasmacytic infiltrate enriched with IgG4+ 
plasma cells, a storiform pattern of fibrosis, and 
obliterative phlebitis [1–2].
It predominantly affects middle-aged or elderly 
men, usually with a mild or subacute clinical presentation 
and it may mimic various malignant, infectious and 
inflammatory disorders [3].
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Laboratory investigations show some very frequent, 
albeit non specific, abnormalities [4–6] including 
hypergammaglobulinemia (80–90% of cases), elevated 
(>135 mg/dl) serum IgG4 levels (50–70%), elevated serum 
IgE levels (60–70%), C3 and/or C4 hypocomplementemia 
(50–70%), peripheral eosinophilia (35–50%), antinuclear 
antibodies (30%) and rheumatoid factor (20–30%). 
Cellular immunity, and particularly T-cells are 
implicated in disease pathogenesis. In fact, CD4+ T cells 
are abundant within IgG4-RD lesions, and  tissue T cell 
cytokines (IL-4, IL-10 and TGF-β) are upregulated [7].  A 
polarized type 1 T helper or type 2 T helper cell population 
might act as a critical mediator of fibrosis by secreting 
cytokines such as IFN-γ and TGF-β which recruit and 
activate fibroblasts. A separate T follicular helper cell 
population producing IL-4 and IL-10 might promote class-
switching of IgG antibodies to IgG4 and differentiation of 
B cells into plasma cells [2, 8, 9]. Lastly, regulatory T-cells 
likely play a central role in IgG4 and TGF-β production in 
the interstitium, thus promoting interstitial fibrosis [10].
The kidney is involved in approximately 15% 
of patients [4–6, 8]. Renal involvement, termed IgG4-
related kidney disease (IgG4-RKD), may include a wide 
range of manifestations such as tubulointerstitial nephritis 
(TIN), membranous glomerulonephropathy (MGN), 
pyelitis, and hydronephrosis due to retroperitoneal 
fibrosis (RPF) [8, 11, 12]. Compared to general IgG-
RD patients, IgG4-RKD patients (especially those with 
TIN) more frequently show hypocomplementemia and 
elevated serum IgG4 levels [5, 11–14].
IgG4-related TIN patients may present progressive 
renal failure, mild to moderate proteinuria, leukocyturia, 
and mild haematuria [8, 12, 15–17]. IgG4-related RPF 
patients may show only mild creatinine elevation or even 
normal renal function with normal urinalysis [12, 18]. 
Contrast-enhanced computerized tomography 
(CT), magnetic resonance imaging (MRI) and 
18F-fluorodeoxyglucose (FDG) positron emission tomography/
computed tomography (PET/CT) play an important diagnostic 
role in IgG4-RKD, in particular in patients with RPF, and are 
useful tools for monitoring therapeutic response and guiding 
interventional treatment [5, 12, 19].
Glucocorticoids are the first line of therapy for both 
IgG4-RD [1, 3, 9, 20] and IgG4-RKD [8, 15–17, 21], but 
disease relapse after tapering or discontinuing treatment is 
very high, and long-term use of glucocorticoids is associated 
with various adverse events [8, 9, 21]. Rituximab (RTX) has 
rarely been used as induction therapy but is frequently used 
as second-line therapy, especially in refractory cases [22–25]. 
We previously reported the favourable outcome of a 
cohort of patients with severe SLE treated with intensive B 
cell depletion therapy (IBCDT) consisting of a combination 
of 4 plus 2 infusions of RTX, cyclophosphamide and 
methylprednisolone pulses [26]. This approach made 
administering immunosuppressive maintenance therapy 
to avoid disease relapse unnecessary [27]. Results were 
confirmed in a larger series of patients with lupus nephritis 
followed-up for a mean of 44.5 months [28].
In the present study the effectiveness of IBCDT 
on clinical, biochemical, radiological and histologic 
parameters has been evaluated in patients with severe 
IgG4-related TIN and IgG4-related RPF.
RESULTS
Clinical and laboratory features of IgG4-RKD 
patients
Table 1 shows the baseline and follow-up data of all 
our patients. All the patients were followed-up for 24 months. 
IBCDT resulted in substantial renal functional improvement in 
all patients with TIN (#1, #2 and #3), who showed an increase 
in estimated glomerular filtration rate (eGFR) at 12 months 
from 9 (range, 8–11) to 24 (range, 14–36) ml/min per 1.73 m2. 
This improvement persisted at 24 months (26 ml/min per 1.73 
m2, range, 19–37), and at 36 months in patients #1 and #2 (39 
and 27 ml/min per 1.73 m2, respectively). eGFR values also 
improved at 12, 24 and 36 months in patient #4 (from 48 to 74 
ml/min per 1.73 m2 ), while in patient  #5, who had RPF and 
bilateral ureteral stents, values remained stable six months after 
stent removal (from 44 to 49 ml/min per 1.73 m2).
All immunologic parameters showed a definite 
improvement at 1 year in TIN patients (#1, #2 and #3). In 
particular, total serum IgG decreased from 3,236 (range, 
2,195–5,201) to 706 (range, 571–826) mg/dl;  likewise, IgG4 
subclass decreased from 665 (range, 253–1,390) to 51 (range, 
36–80) mg/dl. Complement mean level increased to normal: 
C3 went from 49 (range, 47–51) to 99 (range, 89–108) mg/
dl; C4 rose from 6 (range, 1–10) to 27 (range, 20–35) mg/dl. 
CD20+ B-cells decreased from the pre-treatment 
mean value of 8.7% (range, 3.1–13) to 0% seven days 
after the 4th infusion (data not shown), and showed a mild 
increase to 0.5% (range, 0.09–1.2) after 12–15 months. 
Circulating regulatory T-cells (reference values, 
0.5–5%) decreased from 7.2% (range, 5.4–9) to 2.5% 
(range, 2.2–3.0) at one year.
The overall changes in immunological parameters 
persisted at 24 months and in patients #1 and #2 even 
at 36 months. Interestingly, patient #3, who had not 
received cyclophosphamide due to a past history of colon 
cancer, showed a definite increase in CD20+ B-cells 
(from 0 to 4.4%) and Treg cells (from 2.2 to 6.1%) at 
24 months.
In the two patients with RPF total IgG, IgG4, CD20+ 
B-cells and Treg cells decreased as expected due to the 
immunosuppressive treatment, while C3 and C4 levels, 
that were already normal, remained unchanged.
Histologic features of IgG4-RKD patients
Patients #1, #2 and #3 underwent a second renal 
biopsy 12 months after the first procedure.
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Figures 1 and 2 depict the histological picture 
at diagnosis and one year later as shown by the serial 
biopsies performed on patients #1 and #2, respectively: 
light microscopy study revealed a remarkable reduction 
of interstitial plasma cell infiltrates. Furthermore, 
immunohistochemistry showed normalization of IgG4/
IgG positive plasma cells (from 40% to 4% and from 60% 
to 2%, respectively). The repeat renal biopsy of patient #3 
showed the same histological improvement.
In particular, the first biopsy in patient #1showed a 
more densely cellular inflammatory lesion with expansile 
storiform interstitial fibrosis involving about 80% of 
the examined material; in the second biopsy there was a 
marked reduction of storiform interstitial fibrosis that 
occupied only about 5% of the evaluated material, with an 
associated evident decrease of the inflammatory component. 
Furthermore, immunofluorescence of the first biopsy 
demonstrated the presence of granular immune deposits 
(IgG, IgM and C3) in the tubular basement membrane 
which became negative in the second one. In patient #2 
the amount of interstitial fibrosis remained substantially 
unchanged between the two biopsies, conversely there were 
only scattered plasma cells with a normal IgG4/IgG ratio in 
the second one. In patient #3 there was a mild reduction of 
Table 1: Clinical, histologic, and laboratory features of patients
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age (yr) 74 70 82 54 73
Sex Male Male Male Male Female
IgG4-RKD TIN TIN TIN RPF RPF
Baseline eGFR
(ml/min per 1.73 m2)
11 8 8 48 63
12-month eGFR
(ml/min per 1.73 m2)
36 23 14 75 44
24-month eGFR
(ml/min per 1.73 m2)
37 22 19 75 49
36-month eGFR
(ml/min per 1.73 m2)
39 27 74
Baseline sIgG (mg/dl) 2,195 5,201 2,312 1,034 1,387
12-month sIgG (mg/dl) 721 826 571 839 372
24-month sIgG (mg/dl) 1,026 821 695 618 739
36-month sIgG (mg/dl) 1,421 898 652
Baseline sIgG4 (mg/dl) 354 1,390 253 136 215
12-month sIgG4 (mg/dl) 39 80 36 70 N.A.
24-month sIgG4 (mg/dl) 215 37 17 42 19
36-month sIgG4 (mg/dl) 299 35 41
Baseline sC3/C4 (mg/dl) 51/10 47/1 50/8 141/32 138/28
12-month sC3/C4 (mg/dl) 108/35 102/20 89/28 144/35 N.A.
24-month sC3/C4 (mg/dl) 130/56 120/25 90/30 117/29 123/30
36-month sC3/C4 (mg/dl) 95/27 100/18 136/31
Baseline CD20+ (%) 10 3.1 13 6.6 10.8
12-month CD20+ (%) 1.2 0.09 0.0 5 0.0
24-month CD20+ (%) 1.2 0.08 4.4 0.0 5.6
36-month CD20+ (%) 1.4 0.16 0.1
Baseline Tregs (%) 9.0 5.4 N.A. 5.0 1.9
12-month Tregs (%) 3.0 2.5 2.2 5.5 1.0
24-month Tregs (%) 3.8 4.9 6.1 2.6 5.0
36-month Tregs (%) 4.9 5.5 0.9
Abbreviations: yr, year; IgG4-RKD, IgG4-related kidney disease; TIN, Tubulointerstitial nephritis; RPF, retroperitoneal 
fibrosis; eGFR, estimated glomerular filtration rate; sIgG, serum IgG; Tregs, regulatory T cells; N.A., not available.
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interstitial fibrosis between the two biopsies, but the second 
one showed only focal aspects with a storiform pattern and 
occasional plasma cells.
Figure 3 illustrates light microscopy and 
immunohistochemistry findings of the surgical periaortic 
tissue biopsy performed on patient #4 which shows a dense 
lymphoplasmacytic infiltrate, the characteristic storiform 
pattern of fibrosis and  >30 IgG4+ plasma cells/HPF.  
Radiologic features of IgG4-RKD patients
Figure 4 shows the evolution of retroperitoneal, 
periaortic tissue in patient #4: a 60% reduction 
in  thickness was evident at 5 months, but a new 
increase in the fibro-inflammatory mass due to disease 
reactivation was seen at 16 months. Interestingly, none 
of the immunologic parameters (total IgG, IgG4, C3/
C4, CD20+ B-cells, Treg cells) showed any changes 
that might suggest this disease relapse. The patient 
was therefore treated with oral steroids which were 
gradually tapered during the following 3 months, and 
with RTX 375 mg/m2 every 4 months, showing again a 
gradual reduction of retroperitoneal tissue in MRI and 
PET/CT studies.
Figure 5 shows radiologic imaging performed on 
patient #5 before starting the IBCDT protocol and at 
six months: complete disappearance of retroperitoneal 
and perivascular fibroinflammatory tissue on CT scan is 
evident, with persistent residual minimal pelvic metabolic 
activity on PET/CT study. After 14 months, ureteral stents 
were removed without the reappearance of hydronephrosis 
in the subsequent MRI study.
Treatment-related complications of IgG4-RKD 
patients
Patients #1 and #2 developed steroid-induced 
diabetes mellitus requiring transient insulin therapy 
Figure 1: Light microscopy and immunohistochemistry findings in patient #1. Plasma cell infiltrate before (A) and after 
(B) intensive B cell depletion therapy (IBCDT). IgG+ plasma cells before (C) and after (D) IBCDT. (A) Masson’s trichrome (original 
magnification ×100); (B) Periodic acid-Schiff solution (PAS) (original magnification ×100); (C, D) Immunohistochemical staining 
(original magnification ×200).
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that was eventually discontinued in conjunction with 
prednisone discontinuation.
Patient #4 developed mild, acute bronchopneumonia 
during the course of immunosuppressive treatment, which 
was rapidly and completely controlled by oral antibiotics.
DISCUSSION
Glucocorticoids represent the first line of therapy for 
both IgG4-RD (1, 2, 9, 20) and IgG4-RKD (8, 15–17, 21).
A starting prednisolone dose of 0.6–1.0 mg/kg/
daily, gradually tapered after 2–4 weeks depending on 
the clinical response, is the usual approach for IgG4-RD 
patients with organ failure, in particular in cases of type 
1 autoimmune pancreatitis, and clinical and laboratory 
improvements are frequently rapid, depending on the 
affected organs and the degree of fibrosis [1, 2, 9]. 
Nevertheless, although the initial response is often good, 
disease relapse after tapering or discontinuing steroids 
is very high [9]. Furthermore, steroid therapy exposes 
patients to several possible adverse side effects, so 
immunosuppressants such as azathioprine, mycophenolate 
mofetil, methotrexate and cyclosporine have been used 
as glucocorticoid-sparing agents, or in patients showing 
incomplete response. However, their efficacy has not been 
demonstrated [2, 9]. 
RTX has been shown to be effective in improving 
clinical and serologic features of IgG4-RD patients with 
active inflammation [20–23], even without concomitant 
steroid therapy [24]. Treatment with RTX can decrease serum 
IgG4, with serum IgG4 concentrations remaining low (and 
disease quiescent) even after B cell reconstitution [23]. 
Steroids are effective for most patients with IgG4-
related TIN [13, 16, 21] and for some patients with IgG4-
related RPF [18]. However, recovery of renal function 
may be incomplete. Furthermore, relapse of renal 
dysfunction following steroid tapering or discontinuation 
is frequently observed, and irreversible renal failure may 
occur, especially in patients with advanced renal damage 
[8, 17, 21]. Compared to glucocorticoids, RTX might yield 
a more effective and long-lasting response in IgG4-RKD 
patients. This is a relatively unexplored field because, 
apart from preliminary data from our group [12] and a 
recent report on IgG4-related aggressive TIN [30], RTX 
has not yet been used in the specific population of IgG4-
RKD patients.
Figure 2:  Light microscopy and immunohistochemistry findings in patient #2. Plasma cell infiltrate and storiform fibrosis 
before (A) and after (B) intensive B cell depletion therapy (IBCDT). IgG+ plasma cells before (C) and after (D) IBCDT. (A) Periodic acid-
Schiff solution (PAS) (original magnification ×100); (B) Masson’s trichrome (original magnification ×200); (C, D) Immunohistochemical 
staining (original magnification ×200).
Oncotarget21342www.oncotarget.com
An international panel of experts very recently 
developed some recommendations for the management 
of IgG4-RD, confirming glucocorticoids as first-line 
agents for remission induction in all patients with 
active, untreated disease (94% agreement). Conversely, 
there was lower agreement (46%) on the use of steroid-
sparing agents, including RTX [31], possibly due to the 
insufficient difference between results obtained with 
steroids compared to RTX given alone.
In the present case series, we treated 1 patient who 
had IgG4-related TIN with a combination therapy of 
steroids and RTX, and 4 patients (2 with IgG4-related 
TIN and 2 with IgG4-related RPF) with the intensified 
immunosuppressive protocol adopted in our Department 
for severe SLE nephritis [26, 28]. In these 4 patients 2 
pulses of intravenous cyclophosphamide were added to 
steroids and RTX because of rapidly progressive renal 
failure or severe histological activity or high metabolic 
activity at radiologic investigation.
The rationale for the combination therapy with 
small doses of cyclophosphamide over rituximab alone 
relies both on taking advantage of the synergic effects 
with RTX on CD20 positive cells and on expanding 
immunomodulation over a wider spectrum of B cells like 
plasmablasts also inhibiting their antigen presenting cell 
function. In our opinion this intensified treatment could be 
taken into consideration in patients with very aggressive 
clinical and histologic forms of IgG4-RKD and who may 
require more rapid and efficient induction therapy. Due to 
the small sample of patients additional studies are required 
to confirm this observation.
Actually, patients with IgG4-related TIN, 
characterized by extremely reduced eGFR at presentation 
showed a remarkable response both in renal function and 
Figure 3: Light microscopy and immunohistochemistry findings in patient #4. Dense plasma cell infiltrate (A) and storiform 
fibrosis (B) in surgical periaortic tissue biopsy, typical of IgG4-related retroperitoneal fibrosis. IgG+ plasma cells (C), and IgG4+ plasma 
cells (D). (A) hematoxylin and eosin (original magnification ×100); (B) Masson’s trichrome (original magnification ×100); (C, D) 
Immunohistochemical staining (original magnification ×400).
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in immunologic parameters. Despite the severity of the 
disease in our series, these effects still persisted without 
any further immunomodulatory or anti-inflammatory 
therapy 2 years later, which is in line with the results 
already observed in severe SLE patients with long term 
follow-up  (44 months) [28]. Furthermore, the three repeat 
renal biopsies performed one year after presentation, 
i.e., 6–8 months after completely discontinuing therapy, 
showed only modest plasma cell infiltration, further 
supporting the long term effects of IBCDT. Of note, 
with regard to the interstitial fibrosis, the peculiar 
storiform pattern characterizing IgG-RD was less evident 
[12]. Interestingly, patient #3, who did not receive 
cyclophosphamide due to a past history of colon cancer 
showed an increase of CD20+ B-cells (from 0 to 4.4%) 
and Treg cells (from 2.2 to 6.1%) at 24 months; the less 
aggressive immunosuppression may have facilitated this 
increase, but whether these immunologic modifications 
might predict disease relapse remains to be confirmed.
Normalization of circulating regulatory T-cells at the 
end of therapy, together with the functional, immunological 
and histological improvement observed in our TIN patients 
support a role for these cells in the pathogenesis of IgG4-
RD as proposed by Takeuchi et al. [7] and suggest their 
potential usefulness in the follow-up of patients.
With regard to IgG4-related RPF, the high recurrence 
rate often requires maintenance immunosuppressive therapy 
[32]. The clinical course of our patient with the longer 
follow-up confirms the need for continuous monitoring with 
MRI or PET/CT (performed at 6–12 month- intervals for at 
least 3 years) in order to identify disease reactivation.  
The main limitations of our study are the small 
number of patients, the population heterogeneity and the 
limited follow-up. In particular, the three patients with TIN 
Figure 4: Radiologic features of patient #4. Magnetic resonance and PET/CT imagings before (A, B), 5 months (C), and 16 months 
(D) after treatment: (A and B) abnormal periaortic soft tissue, axial diameter 17 mm, showing high metabolic activity; (C) 60% reduction 
of tissue axial thickness; (D) 80% increase of periaortic mass axial diameter.
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showed different immunologic parameters as compared to 
RPF patients  including higher levels of serum IgG, IgG4, 
circulating T regulatory cells, and lower complement levels. 
Some of these features have been already described [8, 11, 
13, 14], and could suggest slightly different, organ-specific, 
pathogenetic mechanisms, but the actual significance 
remains to be elucidated. Notably, severe renal involvement 
is quite exceptional in IgG4-RD which is per se a very rare 
disease. This is a typical condition that makes the possibility 
of a randomized controlled study highly unrealistic.
The main strength of this study is that it is the first 
case series study to include repeat renal biopsies. Re-
examination of histology one year after diagnosis and 
therapy helps guide further therapeutic decisions, provides 
insight into the possible progression of the disease or, as in 
our cases, supports discontinuation of therapy.
MATERIALS AND METHODS
Patients and design
Between October, 2013 and October, 2015 five 
consecutive patients (4 men and 1 woman) were found 
to have IgG4-related kidney disease in our Unit. Three 
patients had histologically-proven IgG4-related TIN, while 
two patients had histologically-proven IgG4-related RPF. 
Figure 5: Radiologic features of patient #5. CT scan and PET/CT imagings before starting therapy (A, C) and at 6 months (B, D): 
(A) retroperitoneal and perivascular fibroinflammatory tissue, with (C) high metabolic activity; (B) complete disappearance of abnormal 
tissue, with (D) persistence of residual minimal pelvic metabolic activity.
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Renal and retroperitoneal tissue specimens were examined 
by light microscopy and immunohistochemistry. 
Diagnosis of IgG4-related TIN was based on 
Raissian’s criteria [13], while histological evaluation 
of tissue specimens from the patients with RPF was 
performed according to the consensus statement proposed 
by Deshpande et al. [29]. 
A previous diagnosis of Sjogren-like syndrome 
had been made in patient #1, who was treated with small 
doses of oral prednisone. One year later, he was admitted 
to our  Division for rapidly progressive renal failure. Renal 
biopsy showed an IgG4-related TIN.
Patient #2 had been mono-nephrectomized in 
another hospital due to a suspected neoplasm with a 
final  histological diagnosis of xanthogranulomatous 
pyelonephritis 16 months before coming to our 
observation.  He was admitted to our  Division for rapidly 
progressive renal failure and underwent renal biopsy, 
which showed a typical  IgG4-related TIN.
Patient #3 had undergone colon resection 20 years 
earlier due to a malignant tumour. He was admitted to 
our Division for acute renal failure overlapping chronic 
impairment. Renal biopsy showed an IgG4-related TIN.
Patient #4, who had been admitted for lower 
back pain and mild acute renal failure, showed bilateral 
hydroureteronephrosis due to retroperitoneal and periaortic 
abnormal tissue observed both at ultrasound and CT 
imaging. He underwent an exploratory laparotomy, and 
the tissue specimen showed features of IgG4-related RPF.
Patient #5 underwent radical hysteroannessiectomy 
10 months earlier due to suspected uterine cancer with 
secondary, initially monolateral, hydroureteronephrosis. 
She required bilateral ureteral stent placement for recurrent 
hydronephrosis due to the presence of abnormal pelvic 
and periureteral tissue, characterized by high metabolic 
activity at the FDG-PET/CT. After admission to our Unit, 
re-examination of the surgical specimen confirmed the 
suspicion of histologically active IgG4-related RPF.
Estimated GFR using the CKD-EPI formula, blood 
count, IgG/IgG4, C3/C4, CD20+ cells and circulating Tregs 
were measured at baseline and during follow-up in all patients.
Contrast-enhanced CT or MRI and  FDG-PET/CT 
were performed at baseline and during follow-up in both 
patients with RPF.
Percutaneous needle biopsy was repeated in all the 
patients with TIN one year after the initial histological 
diagnosis. 
Renal and periaortic tissue pathology
Renal samples were obtained by real-time 
ultrasound-guided percutaneous needle biopsy in 
patients #1, #2, and #3. Periaortic tissue was obtained 
by open biopsy of the mass lesion in patient #4 and by 
surgical hysteroannessiectomy in patient #5. Renal and 
periaortic tissue specimens were processed for light and 
immunofluorescence microscopy. Immunostaining was 
performed using anti-IgG and anti-IgG4 antibodies.
Treatment protocol
Patients #1, #2, #4 and #5 were treated according to 
the IBCDT protocol previously described by our group in 
severe cases of SLE with nephritis [26]. They intravenously 
received 3 pulses of 15 mg/kg methylprednisolone 
followed by oral prednisone (0.8 mg/kg/day, gradually 
tapered until discontinuation in 4 months) plus 2 pulses 
of 500–750 mg cyclophosphamide (on days 1 and 15) 
plus 4 weekly Rituximab administrations (375 mg/m2). 
Two more doses of Rituximab were administered 1 and 2 
months following the last weekly infusion. 
In patient #3 cyclophosphamide was avoided due to 
his past history of colon cancer.
Patients #2 and #5 received isoniazid prophylaxis 
due to a positive QuantiFERON-TB Gold test result.
CONCLUSIONS
IgG4-RKD may be a progressive disease that, if 
untreated, can lead to chronic renal failure and dialysis. 
Steroid treatment may be insufficient in the most severe 
forms of IgG4-TIN showing severe tubular atrophy and 
interstitial fibrosis as well as in cases of IgG4-RPF with 
widespread involvement. Furthermore its use is limited by 
several adverse effects, particularly in elderly patients. 
In our small sample of patients with aggressive 
disease, IBCDT has proved to be effective and safe. These 
preliminary observations warrant future studies.
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